Back to Articles
48862026 Q3PrimeJGAAP

ASKA Pharmaceutical Holdings (4886) FY2026 Q3 Earnings Report

For FY2026 Q3, revenue came to ¥54.5B (+9.1% year on year) and operating income ¥4.9B (-10.6%). The segment drivers and cash flow follow.

Pharmaceutical


Quick View

MetricCurrentPriorYoY
Revenue¥544.9B¥499.3B+9.1%
Operating Income¥49.1B¥55.0B−10.6%
Ordinary Income¥48.5B¥54.5B−10.9%
Net Income¥40.3B¥41.0B−1.7%
ROE5.4%5.7%-

Executive Summary

Key Metrics

Cash Flow Analysis

Earnings Quality

Risk Factors

Industry Benchmark (Reference - Proprietary Data)

Key Takeaways from Earnings


**